Adult cancer pain

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 8, 2013, Pages 992-1022

  Swarm, Robert A ^a   Abernethy, Amy Pickar ^b   Anghelescu, Doralina L ^c   Benedetti, Costantino ^d   Buga, Sorin ^e   Cleeland, Charles ^f   DeLeon Casasola, Oscar A ^g   Eilers, June G ^h   Ferrell, Betty ⁱ   Green, Mark ^u   Janjan, Nora A ^f   Kamdar, Mihir M ^j   Levy, Michael H ^k   Lynch, Maureen ^l   McDowell, Rachel M ^m   Moryl, Natalie ⁿ   Nesbit, Suzanne A ^o   Paice, Judith A ^p   Rabow, Michael W ^q   Syrjala, Karen L ^r   Urba, Susan G ^s   Weinstein, Sharon M ^t   more..

^a BARNES JEWISH HOSPITAL   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h NEBRASKA MEDICAL CENTER   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^m VANDERBILT INGRAM CANCER CENTER   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r SEATTLE CANCER CARE ALLIANCE   (United States)

^s UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^t UNIVERSITY OF UTAH   (United States)

^u NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE PHOSPHATE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE;

ARTICLE; CANCER PAIN; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; ONCOLOGY; PAIN ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE;

ACETAMINOPHEN; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; SOCIAL SUPPORT;

EID: 84882957478     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0119     Document Type: Article

References (168)

1. Merskey H, Bugduk N. Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, WA: IASP Press; 1994.
2. Cohen MZ, Easley MK, Ellis C, et al. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage 2003;25:519-527.
3. Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005;23:182-190.
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206.
5. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
6. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
7. Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 1997;14:99-117.
8. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
9. Stjernsward J. WHO cancer pain relief programme. Cancer Surv 1988;7:195-208.
10. Stjernsward J, Colleau SM, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage 1996;12:65-72.
11. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Williston Park) 2001;15:1627-1640.
12. Hewitt DJ. The management of pain in the oncology patient. Obstet Gynecol Clin North Am 2001;28:819-846.
13. Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer 1989;63:2298-2307.
14. Hicks CL, von Baeyer CL, Spafford PA, et al. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001;93:173-183.
15. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
16. Soetenga D, Frank J, Pellino TA. Assessment of the validity and reliability of the University of Wisconsin Children's Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs 1999;25:670-676.
17. Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. Pain Manag Nurs 2006;7:117-125.
18. Al-Atiyyat HN. Cultural diversity and cancer pain. J Hosp Palliat Nurs 2009;11:154-164.
19. Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh 2006;38:225-233.
20. Akbik H, Butler SF, Budman SH, et al. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006;32:287-293.
21. Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9:360-372.
22. Webster LR, Webster RM. Predicting aberrant behaviors in opioidtreated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-442.
23. Passik SD, Kirsh KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 2008;16:400-404.
24. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:131-146.
25. Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000;49:796-804.
26. Syrjala KL, Abrams JR, Polissar NL, et al. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain 2008;135:175-186.
27. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, IL: American Pain Society; 2003.
28. Mercadante SL, Berchovich M, Casuccio A, et al. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13-19.
29. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-1700.
30. Mercadante S, Arcuri E, Ferrera P, et al. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005;30:485-491.
31. Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med 2003;4:277-294.
32. Gordon DB, Pellino TA, Miaskowski C, et al. A 10-year review of quality improvement monitoring in pain management: recommendations for standardized outcome measures. Pain Manag Nurs 2002;3:116-130.
33. Sun VC, Borneman T, Ferrell B, et al. Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage 2007;34:359-369.
34. Lin CC, Chou PL, Wu SL, et al. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain 2006;122:271-281.
35. Chang MC, Chang YC, Chiou JF, et al. Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. Cancer Nurs 2002;25:470-476.
36. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000;55:713-719.
37. Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000;44:656-664.
38. Foley KM. The treatment of pain in the patient with cancer. CA Cancer J Clin 1986;36:194-215.
39. Cherny NI. The pharmacologic management of cancer pain. Oncology (Williston Park) 2004;18:1499-1515.
40. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-593.
41. Kornick CA, Santiago-Palma J, Khojainova N, et al. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 2001;92:3056-3061.
42. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805- 811.
43. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009;115:2571-2579.
44. Kleeberg UR, Filbet M, Zeppetella G. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011;11:185-190.
45. Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6- glucuronide after intravenous administration. Eur J Pain 1997;1:185- 190.
46. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-265.
47. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29(Suppl 5):S57-66.
48. Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-550.
49. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine- 3-glucuronide. Life Sci 2001;69:409-420.
50. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol 2010;11:484-489.
51. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995;61:47-54.
52. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13-19.
53. Andersen G, Jensen NH, Christrup L, et al. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med 2002;16:107-114.
54. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-528.
55. Davis MP, Varga J, Dickerson D, et al. Normal-release and controlledrelease oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003;11:84-92.
56. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007;9:298-307.
57. Adam Z, Pour L, Krejci M, et al. Treatment of AL-amyloidosis- results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in ALamyloidosis. Vnitr Lek 2010;56:190-209.
58. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911-918.
59. Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag 2008;4:777-787.
60. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442-451.
61. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-2904.
62. Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002;96:325-328.
63. Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520-528.
64. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504.
65. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-805.
66. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
67. Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010;13:33-38.
68. Rodriguez RF, Bravo LE, Castro F, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56-60.
69. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.
70. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804-2818.
71. Hartrick CT, Rodriguez Hernandez Jr. Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother 2012;13:283-286.
72. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505.
73. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-1804.
74. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebocontrolled trial. Curr Med Res Opin 2011;27:151-162.
75. Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775-1779.
76. Pergolizzi JV, Jr., Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517-1528.
77. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297-326.
78. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012;11:CD003351.
79. Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611-3617.
80. Bruera E, Kim HN. Cancer pain. JAMA 2003;290:2476-2479.
81. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 2000;7:132-141.
82. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003;17:248-256.
83. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain 2007;130:144-156.
84. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-256.
85. Mercadante S. Comments on Wang et al., PAIN, 67 (1996) 407-416. Pain 1998;74:106-107.
86. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998;74:5-9.
87. Wilson RK, Weissman DE. Neuroexcitatory effects of opioids: patient assessment #57. J Palliat Med 2004;7:579.
88. Moryl N, Carver A, Foley KM. Pain and palliation. In: Holland JF, Frei E, eds. Cancer Medicine. 7th ed. Hamilton, ON: BC Decker Inc; 2006:1113-1124.
89. Moryl N, Obbens EA, Ozigbo OH, Kris MG. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol 2006;4:111-111.
90. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 2005;3:227-237.
91. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237.
92. Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000;19:427-435.
93. Challoner KR, McCarron MM, Newton EJ. Pentazocine (Talwin) intoxication: report of 57 cases. J Emerg Med 1990;8:67-74.
94. Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage 1999;17:70-72.
95. Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson's disease. South Med J 1997;90:1023-1026.
96. Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005;39:727-731.
97. Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007;3:167-170.
98. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130-136.
99. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008;11:575-581.
100. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12:554-562.
101. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35:458-468.
102. Chappell D, Rehm M, Conzen P. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1071; author reply 1071.
103. Sanz Rubiales A, del Valle Rivero ML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1070-1071; author reply 1071.
104. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343.
105. Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996;11:147-153.
106. Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001;35:85-91.
107. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650-660.
108. Gagnon P, Allard P, Masse B, DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412-426.
109. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.
110. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 2009;25:2133-2150.
111. Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10:85-93.
112. NCHS Data Brief. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/nchs/data/databriefs/db81.htm. Accessed July 17, 2013.
113. Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed July 17, 2013.
114. Approved Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed July 17, 2013.
115. NCCN Resource Tool: Risk Evaluation & Mitigation Strategies (REMS). National Comprehensive Cancer Network Web site. Available at: http://www.nccn.org/rems/default.asp. Accessed July 17, 2013.
116. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9:571-591.
117. Manfredi PL, Gonzales GR, Sady R, et al. Neuropathic pain in patients with cancer. J Palliat Care 2003;19:115-118.
118. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-581.
119. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007:CD005454.
120. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010;81:1372-1373.
121. Aubert R, Stanek EJ, Yao J, et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract]. J Clin Oncol 2009;27(Suppl):Abstract CRA508
122. Dezentje V, Van Blijderveen NJ, Gelderblom H, et al. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study [abstract]. J Clin Oncol 2009;27(Suppl):Abstract CRA509.
123. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
124. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47.
125. Baron R, Brunnmuller U, Brasser M, et al. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain 2008;12:850-858.
126. Bar Ad V, Weinstein G, Dutta PR, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 2010;116:4206-4213.
127. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 2011;25:553-559.
128. Fleming JA, O'Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381-388.
129. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111-117.
130. Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park) 2001;15:225-234; discussion 234-226.
131. Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-3394.
132. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-1346.
133. Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010;39:548-554.
134. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
135. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-312.
136. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013;119:832-838.
137. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
138. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869-1876.
139. Malviya A, Gerrand C. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med 2012;26:788-796.
140. Raphael J, Hester J, Ahmedzai S, et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010;11:872-896.
141. Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010;28:2565-2570.
142. Stoelb BL, Molton IR, Jensen MP, Patterson DR. The efficacy of hypnotic analgesia in adults: a review of the literature. Contemp Hypn 2009;26:24-39.
143. Huang ST, Good M, Zauszniewski JA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. Int J Nurs Stud 2010;47:1354-1362.
144. Kwekkeboom KL, Cherwin CH, Lee JW, Wanta B. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010;39:126-138.
145. Cassileth BR, Keefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist 2010;15(Suppl 2):19-23.
146. Montgomery GH, Weltz CR, Seltz M, Bovbjerg DH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn 2002;50:17-32.
147. Keefe FJ, Abernethy AP, Campbell LC. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 2005;56:601-630.
148. Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 2012;30:539-547.
149. Puchalski C, Ferrell B, Virani R, et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009;12:885-904.
150. Bennett MI, Bagnall AM, Jose Closs S. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain 2009;143:192-199.
151. Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol 2010;8:52-59.
152. Eidelman A, White T, Swarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw 2007;5:753-760.
153. Tay W, Ho KY. The role of interventional therapies in cancer pain management. Ann Acad Med Singapore 2009;38:989-997.
154. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092-1099.
155. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous imageguided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004;22:300-306.
156. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011:CD007519.
157. Zhang CL, Zhang TJ, Guo YN, et al. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci 2008;53:856-860.
158. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drugrelated toxicity, and survival. J Clin Oncol 2002;20:4040-4049.
159. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15:436-464; discussion 464-436.
160. Rastogi R, Patel T, Swarm RA. Vertebral augmentation for compression fractures caused by malignant disease. J Natl Compr Canc Netw 2010;8:1095-1102.
161. Tancioni F, Lorenzetti MA, Navarria P, et al. Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 2011;9:4-10.
162. Gofeld M, Bhatia A, Burton AW. Vertebroplasty in the management of painful bony metastases. Curr Pain Headache Rep 2009;13:288-294.
163. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011;12:225-235.
164. Eleraky M, Papanastassiou I, Setzer M, et al. Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine. J Neurosurg Spine 2011;14:372-376.
165. Zou J, Mei X, Gan M, Yang H. Kyphoplasty for spinal fractures from multiple myeloma. J Surg Oncol 2010;102:43-47.
166. Flagg A 2nd, McGreevy K, Williams K. Spinal cord stimulation in the treatment of cancer-related pain: "back to the origins". Curr Pain Headache Rep 2012;16:343-349.
167. Dupuy DE, Liu D, Hartfeil D, et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer 2010;116:989-997.
168. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-976.